Literature DB >> 26133520

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment.

P J Vlachostergios1, R L Balmiki2, R Daya2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26133520     DOI： 10.1007/s12094-015-1324-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  33 in total

1.  GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.

Authors:  Eunjung Lee; Peter Nichols; Susan Groshen; Darcy Spicer; Amy S Lee
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

2.  GRP78/BiP is a novel downstream target of IGF-1 receptor mediated signaling.

Authors:  Kyle T Pfaffenbach; Michelle Pong; Todd E Morgan; Hongjun Wang; Kate Ott; Beiyun Zhou; Valter D Longo; Amy S Lee
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

3.  Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.

Authors:  Llana Pootrakul; Ram H Datar; Shan-Rong Shi; Jie Cai; Debra Hawes; Susan G Groshen; Amy S Lee; Richard J Cote
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum.

Authors:  Mario Gonzalez-Gronow; Miguel Cuchacovich; Carolina Llanos; Cristian Urzua; Govind Gawdi; Salvatore V Pizzo
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

5.  Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Authors:  Xinhai Wan; Paul G Corn; Jun Yang; Nallasivam Palanisamy; Michael W Starbuck; Eleni Efstathiou; Elsa M Li Ning Tapia; Elsa M Li-Ning Tapia; Amado J Zurita; Ana Aparicio; Murali K Ravoori; Elba S Vazquez; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Matthew K Iyer; Wallace McKeehan; Vikas Kundra; Fen Wang; Patricia Troncoso; Arul M Chinnaiyan; Christopher J Logothetis; Nora M Navone
Journal:  Sci Transl Med       Date:  2014-09-03       Impact factor: 17.956

Review 6.  Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Authors:  Rahul R Aggarwal; Charles J Ryan; June M Chan
Journal:  Urol Oncol       Date:  2011-06-12       Impact factor: 3.498

7.  Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.

Authors:  Yao Tang; Linbo Wang; Olga Goloubeva; Mohammad Afnan Khan; Bin Zhang; Arif Hussain
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

8.  Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Authors:  Mari Nakabayashi; Lilian Werner; Kevin D Courtney; Geoffrey Buckle; William K Oh; Glen J Bubley; Julia H Hayes; Douglas Weckstein; Aymen Elfiky; Danny M Sims; Philip W Kantoff; Mary-Ellen Taplin
Journal:  BJU Int       Date:  2012-08-29       Impact factor: 5.588

9.  A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death.

Authors:  Danilo Maddalo; Antje Neeb; Katja Jehle; Katja Schmitz; Claudia Muhle-Goll; Liubov Shatkina; Tamara Vanessa Walther; Anja Bruchmann; Srinivasa M Gopal; Wolfgang Wenzel; Anne S Ulrich; Andrew C B Cato
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

10.  miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.

Authors:  S-F Su; Y-W Chang; C Andreu-Vieyra; J Y Fang; Z Yang; B Han; A S Lee; G Liang
Journal:  Oncogene       Date:  2012-10-22       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.